

Karin Jorga, PhD

Publications

- 2022 Savic RM, Green M, Jorga K, Zager M, Washington C.
Model-informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma.
CPT Pharmacometrics Syst. Pharmacol. 11; 687-697, 2022
doi.org/10.1002/psp4.12731
- Green M, Savic RM, Tonda M, Jorga K, Washington C.
Model-informed drug development of voxelotor in sickle cell disease: Exposure-response analysis to support dosing and confirm mechanism of action.
CPT Pharmacometrics Syst. Pharmacol. 11; 698-710, 2022
doi.org/10.1002/psp4.12780
- 2020 Azaro A, Perez Garcia J, Cortes J, Lopez Miranda E, Colombo I, Hess D, Nuciforo P, Vivancos A, Ferrarotto R, Schoenborn-Kellenberger O, Jorga K, Vigolo M, Beni L, Lehal R, Murone M, Bauer M, Pavel P, Vogl F, Stathis A,
Target engagement and clinical safety of CB-103, a first-in-class small molecule inhibitor of the NOYCH transcription complex
[abstract]. ESMO 2020
- 2019 Jorga K, Reigner B, Chavanne C, Alvaro G, Frey N. Pediatric Dosing of Ganciclovir and Valganciclovir: How Model-Based Simulations Can prevent Underexposure and Potential Treatment Failure.
CPT Pharmacometrics Syst. Pharmacol. 8; 167-176, 2019 doi: 10.1002/psp4.12363.
- 2018 Cortes J, Stathis A, Perez J, Mous R, Nuciforo P, Vivancos A, Azaro A, Weber D, Bauer M, Beni L, Lehal R, Jorga K, Schoenborn-Kellenberger O, Garralda E
First-in-human phase 1-2A study of CB-103, an oral pan-NOTCH inhibitor targeting the NOTCH transcription complex in advanced and metastatic solid tumours and haematological malignancies
[abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research (ASCO); 2018 June 1-5; Chicago, IL; J Clin Oncol 36, 2018 (suppl; abstr TPS2619)
- 2016 Jorga K, Chavanne C, Frey N, Lave T, Lukacova V, Parrott N, Peck R, Reigner B. Bottom-up meets top-down: Complementary PBPK and PopPK modeling for regulatory approval of a dosing algorithm of valganciclovir in very young children.
Clin Pharmacol Ther. 100(6); 761-769, 2016 doi: 10.1002/cpt.449.
- Adjei AA, Opyrchal M, Zhao Y, Ma WW, Bakhribah H, Dy GK, Jacob S, O'Hara C, Dozier A, Cmiljanovic N, Schmitz D, Machacek M, Jorga K, Todaro B, Brady W, Dimitrijevic S.
A phase 1 study of the PI3K/mTOR inhibitor PQR309 evaluating safety, pharmacokinetics (PK) and pharmacodynamics (PD) in patients (pts) with advanced solid tumors
[poster abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research; 2016 June 3-7; Chicago, Illinois: ASCO; 2016. Abstract nr 162560.

- 2016 Machacek M, Renaud L, Dimitrijevic S, Schmitz D Ivanova E, Jorga K.
Population Pharmacokinetics of PQR309, a Dual PI3K/mTor Inhibitor in Adult Patients with Advanced Solid Tumors
[abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research; 2016 June 3-7; Chicago, Illinois: ASCO; 2016. Abstract nr 165932.
- Jorga K, Schmitz D, Cmiljanovic N, Fabbro D, Dimitrijevic S.
Exploring intermittent dosing schedules for the Pan PI3K/mTor inhibitor PQR309
[abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, Louisiana: AACR; 2016. Abstract nr 378.
- Jorga K, Huehn E, Fraczekiewicz G, Schmitz D, Fabbro D, Dimitrijevic S.
Concomitant administration of acid reducing agents can impact the pharmacokinetics of the balanced pan-PI3K and mTOR inhibitor PQR309
[abstract]. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology; 2016 Apr 16-20; New Orleans, Louisiana: AACR; 2016. Abstract nr 382.
- 2012 Bai S, Jorga K, Xin Y, Jin D, Zheng Y, Damico-Beyer L, Gupta M, Tang M, Allison D, Lu D, Zhang Y, Joshi A and Dresser M
A Guide to Rational Dosing of Monoclonal Antibodies
Clin Pharmacokinet 51 (2): 119-135, 2012
- 2011 Graham R, Lum B, Morrison G, Chang I, Jorga K, Dean B, Shin YG, Yue Q, Mulder T, Malhi V, Xie M, Low JA, Hop CE.
A single dose mass balance study of the hedgehog pathway inhibitor vismodegip (GDC-0449) in humans using accelerator mass spectrometry.
Drug Metab Dispos, 39(8); 1460-7, 2011
- Graham R, Lum B, Cheeti S, Jin J, Jorga K, Von Hoff D, Rudin CM, Reddy J, Low J, Lo Russo PM.
Pharmacokinetics of hedgehog pathway inhibitor GDC-0449 in patients with locally-advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding
Clinical Cancer Research, 17; 2512-2520, 2011
- 2010 Snoeck E, Chanu P, Laveille M, Jaqmin P, Jonsson EN, Jorga K, Goggin T, Grippo J, Jumbe NL, Frey N.
A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure
Clin Pharmacol Ther, 87(6); 706-7013, 2010
- 2009 Claret L, Girard P, Hoff P, Van Cutsem E, Zuideveld K, Jorga K, Fagerberg J, Bruno R.
Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics
Journal of Clinical Oncology 27; 4103-4108, 2009
- 2008 Snoeck E, Hadziyannis S, Puoti C, Swain M, Berg T, Marcellin P, Zarski JP, Jorga K, Zeuzem S
Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon alfa-2a (40KD) plus ribavirin
Liver International, 28(1); 61-71, 2008

- 2007 Jauslin P, Silber H, Frey N, Gieschke R, Simonsson U, Jorga K, Karsson M.
An Integrated Glucose-Insulin Model to Describe Oral Glucose Tolerance Test
Data in Type 2 Diabetics
The Journal of Clinical Pharmacology, 47, 1244-1255, 2007
- Cosson V, Jorga K, Fuseau E
Modelling of Metabolite Pharmacokinetics in a Large Pharmacokinetic Data Set:
An Application
In "Pharmacometrics. The Science of Quantitative Pharmacology. Ette EI, Williams PJ
(eds), John Wiley & Sons, Hoboken, New Jersey, 2007
- 2006 Wade J, Snoeck E, Duff F, Lamb M, Jorga K.
Pharmacokinetics of ribavirin in patients with hepatitis C virus
British Journal of Clinical Pharmacology, 62, 710-714, 2006
- Snoeck E, Wade J, Duff F, Lamb M, Jorga K.
Predicting sustained virological response and anaemia in chronic hepatitis C
patients treated with peginterferon alfa-2a (40KD) plus ribavirin
British Journal of Clinical Pharmacology, 62, 699-709, 2006
- Jones HM, Parrott N, Jorga K, Lavé T.
A novel strategy for physiologically based predictions of human
pharmacokinetics.
Clinical Pharmacokinetics, 45(5), 511-542, 2006
- Gueorguieva I, Aarons L, Ogungbenro K, Jorga K, Rodgers T, Rowland M.
Optimal Design of Multivariate Response Pharmacokinetic Models
Journal of Pharmacokinetics and Pharmacodynamics, 33(2), 97-124, 2006
- 2002 Coleman MD, Hadley S, Perris AD, Jorga K, Seydel JK
Studies on the toxicity and efficacy of some ester analogues of dapsone in vitro
using rat and human tissues
Environment Toxicology and Pharmacology 12, 7-13, 2002
- Grub S, Schwarzwald H, Kline M, Jorga K
Pharmacokinetics of saquinavir in children during long-term treatment of HIV
infection
The Pediatrics Infectious Disease Journal 21, 712-713, 2002
- Coleman MD, Hadley S, Perris AD, Jorga K, Seydel JK
Studies on the toxicity and efficacy of some ester analogues of dapsone in vitro
using rat and human tissues
Environ Toxicol Pharmacol 12(1), 7-13, 2002
- Grub S, DeLora P, Lüdin E, Duff F, Fletscher C, Brundage R, Kline M, Calles N,
Schwarzwald H, Jorga K
Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients
with human immunodeficiency virus infection
Clin Pharmacol Ther 71, 122-130, 2002

- 2002 Ceravolo R, Piccini P, Bailey DL, Jorga KM, Bryson H, Brooks DJ
18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in
Parkinson's disease.
Synapse 43, 201-207, 2002
- 2001 Buss N, Snell P, Bock J, Steimer JL, Hsu A, Jorga K
Saquinavir pharmacokinetics following combined ritonavir and saquinavir (soft
gelatin capsules) anti-retroviral therapy
British Journal of Clinical Pharmacology 52, 255-264, 2001
- Kline M, Brundage R, Fletcher C, Schwarzwald H, Calles N, Buss N, Snell P, DeLora P,
Eason M, Jorga K, Craig C, Duff F
Combination therapy with saquinavir soft gelatin capsules in children with
human immunodeficiency virus infection.
Pediatr Infect Dis J 20, 666-71, 2001
- Grub S, Bryson H, Goggin T, Lüdin E, Jorga K
The interaction of saquinavir (soft gelatin capsules) with ketoconazole,
erythromycin and rifampicin: comparison of the effect in healthy volunteers and
HIV-infected patients
Eur J Clin Pharmacol 57, 115-121, 2001
- 2000 Jorga KM and van Brummelen P
Drug Development: Experiences with the COMT-Inhibitor Tolcapone for the
Treatment of Parkinson's Disease
MEDCHEM NEWS (Japanese), 10 (3), 2000
- Jorga KM, Fotteler B, Modi M, Rabbia M
Effect of tolcapone on the hemodynamic effects and tolerability of desipramine
European Neurology, 44, 94-103, 2000.
- Jorga K, Banken L, Fotteler B, Snell P, Steimer JL
Population pharmacokinetics of levodopa in parkinsonian patients treated with
tolcapone
Clinical Pharmacology and Therapeutics, 67, 610-620, 2000.
- Jorga KM, Fotteler B, Gasser R, Banken L
Lack of interaction between tolcapone and tolbutamide in healthy volunteers
Journal of Clinical Pharmacology, 40, 544-551, 2000
- Jorga KM, Davis TL, Kurth MC, Saint-Hilaire MH, LeWitt PA, Fotteler B, Zürcher G,
Rabbia M.
Clinical, pharmacokinetic and pharmacodynamic effects of tolcapone withdrawal
in levodopa-treated parkinsonian patients
Clinical Neuropharmacology, 23, 98-105, 2000
- Jorga K, Fotteler B, Banken L, Snell P, Steimer JL
Population pharmacokinetics of tolcapone in parkinsonian patients in dose
finding studies
British Journal of Clinical Pharmacology, 49, 39-48, 2000.

- 1999 Schneider E and Jorga K
L-DOPA
In "Neuro-Psychopharmaka", Bd. 5, 2. Aufl. Riederer P./Laux G./ Pöldinger (Hrsg.),
Springer-Verlag, Wien, 1999
- Jorga KM, Fotteler B, Heizmann P, Gasser R
Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-
methyltransferase
British Journal of Clinical Pharmacology, 48, 513-520, 1999.
- Jorga KM and Nicholl DJ
COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in
parkinsonian patients on levodopa/carbidopa (Sinemet®)
British Journal of Clinical Pharmacology, 48, 449-452, 1999.
- Jorga K.
L-DOPA Pharmakokinetik unter COMT-Hemmung.
In: Pharmakotherapie der Parkinson-Krankheit. Oertel WH (Ed.). Roche Editiones,
Basel, 31-42, 1999.
- Gasser UE, Jorga K, Crevoisier C, Hovens SEL, van Giersbergen PLM
COMT inhibition by tolcapone further improves levodopa pharmacokinetics
when combined with a dual-release formulation of levodopa/benserazide
Eur. Neurol. 41, 206-211, 1999
- Jorga KM, Larsen JP, Beiske A, Schleimer M, Fotteler B, Schmitt M, Moe B.
The effect of tolcapone on the pharmacokinetics of benserazide
European Journal of Neurology, 6, 211-219, 1999
- 1998 Jorga KM, Fotteler B, Heizmann P, Zürcher G.
Pharmacokinetics and pharmacodynamics after oral and intravenous
administration of tolcapone, a novel adjunct to Parkinson's disease therapy
European Journal of Clinical Pharmacology, 54, 443-447, 1998
Jorga KM, Kroodsma JM, Fotteler B, Heizmann P, Meyer J, Rasch MC, van Hattum J.
The effect of liver impairment on the pharmacokinetics of tolcapone and its
metabolites
Clinical Pharmacology and Therapeutics, 63, 646-54, 1998
- Jorga K, Fotteler B, Sedek G, Nielsen T, Aitken JW.
The effect of tolcapone on levodopa pharmacokinetics is independent of
levodopa/carbidopa formulation
Journal of Neurology, 245, 223-230, 1998.
- Jorga KM.
Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of
early studies in volunteers.
Neurology, 50 (Suppl 5), S29-S36, 1998
- Jorga KM.
COMT Inhibitors: Pharmacokinetic and Pharmacodynamic Comparisons.
Clin. Neuropharmacol. 21 (Suppl. 1), S9-S16, 1998.

- 1997 Sedek G, Jorga KM, Burns R, Schmitt M, Leese P
Effect of tolcapone on plasma levodopa levels after coadministration with levodopa/carbidopa to healthy volunteers.
Clin. Neuropharmacol., 10, 531-541, 1997
- Jorga KM, Sedek G, Fotteler B, Zuercher G, Nielsen T, Aitken JW.
Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.
Clin. Pharmacol. Ther. 62, 300-310, 1997.
- Jorga K, Banken L, Fotteler B
Prospective PK/PD Population Analysis in the Clinical Development of Tolcapone: A COMT Inhibitor for the Treatment of Parkinson's Disease
In "COST B1, medicine. European cooperation in the field of scientific and technical research. The population approach: measuring and managing variability in response, concentration and dose." Aarons (ed.), Office for Official Publications of the European Communities (EUR 17611 EN), Luxemburg, 1997
- Jorga K, Fotteler B, Schmitt M, Nielsen T, Zuercher G, Aitken JW.
The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations.
Eur. Neurol. 38, 59-67, 1997
- Jorga K.
Pharmakologie der COMT-Hemmer.
In: Parkinson-Krankheit - Entwicklungen in Diagnostik und Therapie. Fischer PA (Ed.). Roche Editiones, Basel, 239-257, 1997.
- Dingemans J, Wood N, Jorga KM, Kettler R.
Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazabemide in healthy subjects.
Br. J. Clin. Pharmacol. 43, 41-47, 1997
- 1996 Dingemans J, Jorga KM, Zuercher G, Fotteler B, Sedek G, Nielsen T and van Brummelen P.
Multiple-dose clinical pharmacology of the catechol-O-methyltransferase inhibitor tolcapone in elderly subjects.
Eur. J. Clin. Pharmacol. 50, 47-55, 1996
- Da Prada M, Jorga KM.
Response to Garrido et al.: Side Effects of the Catechol-O-Methyl-Transferase Inhibitor Ro 40-7592 in Rabbits"
Clin. Neuropharmacol. 19, 98-99, 1996
- 1995 Dingemans J, Jorga KM, Zuercher G, Schmitt M, Sedek G, Da Prada M and van Brummelen P.
Pharmacokinetic-Pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa.
Br. J. Clin. Pharmacol. 40, 253-262, 1995

- 1995 Dingemanse J, Jorga KM, Schmitt M, Gieschke R, Fotteler B, Zuercher G, Da Prada M, and van Brummelen P.
Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. *Clin. Pharmacol. Ther.* 57, 508-517, 1995.
- Jorga K, Leenders KL, Guenther I, Psylla M.
COMT inhibition: Pharmacology of tolcapone and 6-[¹⁸F]-Fluoro-L-Dopa (FDOPA) PET results.
In: *PET for Drug Development and Evaluation*. Comar D (Ed.). Kluwer Academic Publishers, The Netherlands, 189-195, 1995.
- 1994 Da Prada M, Zuercher G, Kettler R, Dingemanse J, Jorga KM, Dubuis R.
Inhibiting MAO-B with lazabemide and COMT with tolcapone.
In: *Antiparkinson Therapy: 20 years of Madopar - new avenues*. Poewe W, Lees A (Eds.). Roche Editions, Basel, 93-111, 1994.